Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

Authors: BR McDonald, T Contente-Cuomo, S-J Sammut, A Odenheimer-Bergman, B Ernst, N...
Research group: Caldas Group
E-pub date: 31 Jul 2019
Journal name: Sci Transl Med

POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

Authors: RD Baird, AG van Rossum, M Oliveira, KJ Beelen, M Gao, M Schrier, IA Mandje...
Research group: Caldas Group
E-pub date: 31 Jul 2019
Journal name: Clin Cancer Res

EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis.

Authors: G Peluffo, A Subedee, NW Harper, N Kingston, B Jovanović, F Flores, LE Ste...
Research group: Caldas Group
E-pub date: 31 May 2019
Journal name: Cancer Res

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Authors: HM Earl, L Hiller, A-L Vallier, S Loi, K McAdam, L Hughes-Davies, AN Harnet...
Research group: Caldas Group
E-pub date: 31 May 2019
Journal name: Lancet

Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.

Authors: J Gómez-Miragaya, A Díaz-Navarro, R Tonda, S Beltran, L Palomero, M Palaf...
Research group: Caldas Group
E-pub date: 31 May 2019
Journal name: Cancer Res

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Authors: S Kurozumi, C Joseph, S Sonbul, S Alsaeed, Y Kariri, A Aljohani, S Raafat, ...
Research group: Caldas Group
E-pub date: 30 Apr 2019
Journal name: Br J Cancer

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

Authors: L De Mattos-Arruda, S-J Sammut, EM Ross, R Bashford-Rogers, E Greenstein, H...
Research group: Caldas Group
E-pub date: 30 Apr 2019
Journal name: Cell Rep

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Authors: EM Tacconi, S Badie, G De Gregoriis, T Reisländer, X Lai, M Porru, C Folio...
Research group: Caldas Group
E-pub date: 30 Apr 2019
Journal name: EMBO Mol Med

EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.

Authors: J Puppe, M Opdam, PC Schouten, K Jóźwiak, EH Lips, T Severson, M van de V...
Research group: Caldas Group
E-pub date: 31 Mar 2019
Journal name: Clin Cancer Res

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Authors: M Abubakar, J Figueroa, HR Ali, F Blows, J Lissowska, C Caldas, DF Easton, ...
Research group: Caldas Group
E-pub date: 31 Mar 2019
Journal name: Mod Pathol

Filters

Research Groups


Core Facilties


Start date
End date